Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionEnrolling Location: Australia - QLD

    A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects , protocol number NCT03093714 FDL169-2015-04

    A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation

    • Age:

      18 Years to 85 Years

    • Mutation(s):

      Homozygous for the F508del-CFTR mutation.

    • FEV1% Predicted:

      (FEV1) >40% of predicted normal for age, sex and height.

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1) , protocol number NCT02707562

    A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation

    • Age:

      >18 years

    • Mutation(s):

      G551D

    • FEV1% Predicted:

      Pre- or post-bronchodilator FEV1 ≥ 40% of predicted normal

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Australia

    A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation , protocol number NCT02514473 VX14-809-109

    A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

    • Age:

      6-11 years

    • Mutation(s):

      homozygous for the F508del CFTR mutation

    • FEV1% Predicted:

      ppFEV1 of ≥70 p

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Queensland University of Technology Contact: Jeremy Russell - phone:07 3069 7552 email: [email protected] To get started, go to: https://rebrand.ly/HYPRS-CF

    Helping Young People Reduce the Stress of Cystic Fibrosis Study , protocol number The HYPRS-CF Study 1800000294 (UHREC Reference number)

    Researchers at QUT are conducting a national, online research study with young people with Cystic Fibrosis (CF). The goal of this study is to learn how young people think and feel about the stress of CF and whether a social robot could possibly help them cope with this stress.

    • Age:

      10-18 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      1

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the U.S.

    Study of VX-445 triple combination in teens and adults with cystic fibrosis who have one copy of F508del and one copy of a gating or residual function mutation , protocol number VX18-445-104 NCT04058353

    This study evaluated the safety and effectiveness of VX-445 (elexacaftor), tezacaftor, and ivacaftor in combination called TRIKAFTA®. This study was for people with CF 12 years and older with one copy of the F508del mutation and one copy of a gating or residual function mutation.

    • Age:

      12 Years and older

    • Mutation(s):

      One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      20 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceCompleted with results Location: Multiple care centres across the US

    Study of QBW276 in adults with CF , protocol number NCT92566044 NOVARTIS CQBW 276X2201

    This study evaluated the safety and tolerability of QBW276, an inhaled drug designed to improve mucus clearance. This study also evaluated how the body processes the drug.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 100%

    • Number of Visits:

      6

    • Length of Participation:

      14 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Roll-over study of ivacaftor in children with CF who have a CFTR gating mutation (Vertex VX-770-109) , protocol number NCT01946412 VERTEX VX-770-109

    This study evaluated the long-term safety of ivacaftor (Kalydeco®) in children with CF. This study was for children who have a CFTR gating mutation and received at least one dose of ivacaftor in the VX11-770-108 study.

    • Age:

      2 years to 5 years

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      7

    • Length of Participation:

      88 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Open-label study of ivacaftor in people with CF who have a non-G551D CFTR gating mutation (Vertex VX-770-112) , protocol number NCT01707290 VERTEX VX-770-112

    This study evaluated the long-term safety of ivacaftor (Kelydeco®) in participants who have a non-G551D CFTR gating mutation. This study was for people who had participated in one of the VX11-770-110, VX12-770111 or VX12-770-113 studies.

    • Age:

      6 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      7

    • Length of Participation:

      2 years

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Florida, USA

    Study of BI 1265162, a mucus clearance drug, in teens and adults with CF. , protocol number NCT04059094 BI 1399-0003

    This study will look at the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs. This study is for people with CF ages 12 and older.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of the triple-combination modulator, elexacaftor/texacaftor/ivacaftor (PROMISE) , protocol number NCT04038047 PROMISE

    This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in people with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects people with CF across many different aspects of the disease.

    • Age:

      12 Years and Older

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      2 years

    Contact us about this clinical Trial >
  • Displaying results 91-100 (of 200)
     |<  <  6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15  >  >|